Press Release

NeoGenomics Reports Second Quarter 2023 Results

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients